- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01715649
Telehealth Remote Patient Monitoring Study in People With Type 2 Diabetes
Evaluation of a Telehealth Intervention Combining Structured Self-Monitoring of Blood Glucose and Nurse Care Coordination Among People With Type 2 Diabetes Noninsulin-Treated
Telehealth remote patient monitoring is a means of using communications technology - such as telephones, computers, and the Internet - to connect patients remotely with their healthcare team from their homes. The investigators hope to learn more about improving healthy behaviors and blood glucose among persons with diabetes using telehealth remote patient monitoring technology to connect directly with nurse care coordinators.
The purpose of this study is to evaluate a process for improving blood glucose and healthy behaviors among people with type 2 diabetes using telehealth remote patient monitoring technology with nurse care coordinators. Some of the people in this study will work with a nurse care coordinator who will review your blood glucose weekly and call you at home every month for 3 months, while some of the people in this study will simply receive their normal care. At the end of the study, every participant will be asked questions about how they feel about their health care.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95833
- Sutter Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Enrolled in diabetes disease management program
- ages 30-70
- HbA1c between 7.5% and 10.9% in the previous six months
- an Internet or 3G connection and email address;
- a working phone line (land line or cellular); and
- ability to read and understand the English language.
Exclusion Criteria:
- taking insulin;
- inability to independently engage in self-management behaviors (diagnosis of dementia, severe depression, schizophrenia, or cognitive impairment);
- severe complications, which would preclude achieving an HbA1c goal of 7% including diagnosis of the following:
- severe stroke;
- heart failure;
- end-stage renal disease;
- kidney dialysis; and
- legally blind.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control-usual care
Nurse care coordination in a telephonic diabetes disease management program
|
|
Experimental: Intervention paired testing and remote monitoring
Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
|
In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit.
Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns.
Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels.
The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin A1c
Time Frame: Change from baseline to 6 months
|
Lab test
|
Change from baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Empowerment
Time Frame: Change from baseline to 3 months
|
Diabetes Empowerment Scale completed by survey
|
Change from baseline to 3 months
|
Behavior Change
Time Frame: Change from baseline to 3 months
|
Summary of Diabetes Self-Care Behaviors scale completed by survey
|
Change from baseline to 3 months
|
Knowledge
Time Frame: Change from baseline to 3 months
|
Michigan Diabetes Knowledge Test completed by survey
|
Change from baseline to 3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of incorporating the intervention into the existing program
Time Frame: 3 months
|
Will include # of participants that complete intervention, #of nurse hours required to analyze data and interact with participant,and number of technology issues impacting use
|
3 months
|
Participant engagement with telehealth technology
Time Frame: 3 months
|
# of participants that complete the 12 week program, # of participants that upload the blood glucose meter values to the technology
|
3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1208042ex
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
Clinical Trials on Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose
-
Biomedical Research Institute of New MexicoSouthern Arizona VA Health Care System; New Mexico VA Healthcare System; Carl...Completed
-
Endocrine Research SocietySuspendedType 2 Diabetes MellitusCanada
-
Manchester University NHS Foundation TrustDexCom, Inc.CompletedDiabetes Mellitus, Type 1United Kingdom
-
Endocrine Research SocietyCompletedType 2 Diabetes MellitusCanada
-
Yuwen ZhangCompletedDiabetes Mellitus, Type 2China
-
HealthPartners InstituteLifeScan; International Diabetes Center at Park NicolletCompletedType 2 DiabetesUnited States
-
Korea UniversityCompletedType 2 DiabetesKorea, Republic of
-
Oregon Health and Science UniversityDexCom, Inc.RecruitingGestational DiabetesUnited States
-
Endocrine Research SocietyCompletedType 2 Diabetes MellitusCanada
-
Endocrine Research SocietySuspendedType 2 Diabetes MellitusCanada